Print Page   |   Contact Us   |   Sign In   |   Join
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 1 of 3
1  |  2  |  3

Scientific Advancements
Tuesday, August 8, 2017   (0 Comments - view/add)
TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensiti »
TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer with...
Thursday, August 3, 2017   (0 Comments - view/add)
Moffitt: New Research Shows the Power of Radiomics to Improve Precision Medicine »
August 3, 2017   Moffitt: New Research Shows the Power of Radiomics to Improve Precision Medicine &n...
Thursday, August 3, 2017   (0 Comments - view/add)
AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigment »
Source: Applied Genetic Technologies Corporation August 3, 2017   AGTC Announces U.S. FDA Orphan Drug...
Monday, July 24, 2017   (0 Comments - view/add)
Xcovery Collaborates with the National Cancer Institute and Children’s Oncology Group for The NCI-CO »
Xcovery Collaborates with the National Cancer Institute and Children’s Oncology Group for The NCI-COG Pediatric MATCH Clin...
Friday, July 14, 2017   (0 Comments - view/add)
StemSynergy Announces Breakthrough in Colorectal Cancer Drug Development »
July 14, 2017 12:12 PM Eastern Daylight Time StemSynergy Announces Breakthrough in Colorectal Cancer Drug Developm...
Tuesday, June 27, 2017   (0 Comments - view/add)
TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targetin »
TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targeting Triple-Negative Brea...
Wednesday, June 21, 2017   (0 Comments - view/add)
CTD Holdings Enrolls First Patient in European Phase I/II Clinical Trial of Trappsol(R) Cyclo(TM) fo »
CTD Holdings Enrolls First Patient in European Phase I/II Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann...
Wednesday, June 21, 2017   (0 Comments - view/add)
Nephure™ Obtains Self-Affirmed GRAS Notification »
June 21, 2017 10:25 AM Eastern Daylight Time Nephure™ Obtains Self-Affirmed GRAS Notification Product ex...
Tuesday, June 20, 2017   (0 Comments - view/add)
Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer »
Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer TAMPA, Fla. , June 20, 2017 /P...
Thursday, June 15, 2017   (0 Comments - view/add)
IND-Enabling Study Data Published in Human Gene Therapy Clinical Development Support Clinical Develo »
IND-Enabling Study Data Published in Human Gene Therapy Clinical Development Support Clinical Development of AGTC-402 for...
Thursday, June 15, 2017   (0 Comments - view/add)
New pathways to cancer therapy »
New pathways to cancer therapy Repurposed antifungal agent exhibits promising efficacy and safety for BCCNS treatment...
Thursday, June 8, 2017   (0 Comments - view/add)
New Zika Test Produces Results In Under An Hour »
SOURCE:  http://health.wusf.usf.edu/post/new-zika-test-produces-results-under-hour#stream/0   New Zi...
Thursday, June 8, 2017   (0 Comments - view/add)
AGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study »
GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ...
Wednesday, June 7, 2017   (0 Comments - view/add)
Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of »
Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut...
Tuesday, May 30, 2017   (0 Comments - view/add)
Somahlution Announces DuraGraft Registry Initiation at Leading Cardiac Surgery Hospitals in Germany »
Somahlution Announces DuraGraft Registry Initiation at Leading Cardiac Surgery Hospitals in Germany The DuraGraf...
Tuesday, May 30, 2017   (0 Comments - view/add)
HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive »
HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update...
Tuesday, May 30, 2017   (0 Comments - view/add)
HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive »
HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update...
Thursday, May 25, 2017   (0 Comments - view/add)
Fruit Flies Journey to International Space Station to Study Effects of Zero Gravity on the Heart »
NEWS RELEASE Media Contacts: Susan Gammon, Ph.D. Sanford Burnham Prebys Medical Discovery Institute Office (858...
Wednesday, May 24, 2017   (0 Comments - view/add)
NovaBone Announces Irrigation Resistant Products with Carriers that have Synergistic Effect in Bone »
NovaBone Announces Irrigation Resistant Products with Carriers that have Synergistic Effect in Bone Formation May 24...
Tuesday, May 23, 2017   (0 Comments - view/add)
Exciting diabetes and obesity research highlights from Medical City »
NEWS RELEASE Media Contact: Deborah Robison Sanford Burnham Prebys Medical Discovery Institute Phone (407) 745-207...
Monday, May 22, 2017   (0 Comments - view/add)
Teewinot Life Sciences Corporation Announces New Cannabis Genome Research Program »
Teewinot Life Sciences Corporation Announces New Cannabis Genome Research Program Furthers Mission to Address Unmet Med...
Tuesday, May 16, 2017   (0 Comments - view/add)
Sanford Burnham Prebys Finds Molecule That Stops Deadly Zika from Spreading »
Sanford Burnham Prebys Finds Molecule That Stops Deadly Zika from Spreading POSTED BY   DEBBIE L. SKLAR &n...
Monday, May 15, 2017   (0 Comments - view/add)
Longeveron Announces Publication of Phase 1 Safety and Efficacy Trial Results for Allogeneic Stem Ce »
Longeveron Announces Publication of Phase 1 Safety and Efficacy Trial Results for Allogeneic Stem Cell Treatment in Frailt...
Wednesday, May 10, 2017   (0 Comments - view/add)
Longeveron Begins Enrollment of Second Cohort of Phase 1 Trial of Allogeneic Mesenchymal Stem Cells »
Longeveron Begins Enrollment of Second Cohort of Phase 1 Trial of Allogeneic Mesenchymal Stem Cells to Treat Alzheimer's D...
Tuesday, May 9, 2017   (0 Comments - view/add)
Biscayne Readies Phase 1b Trial for Novel Antiepileptic Agent BIS-001 and Receives FDA Orphan Drug D »
Biscayne Readies Phase 1b Trial for Novel Antiepileptic Agent BIS-001 and Receives FDA Orphan Drug Designation for Dravet...
Tuesday, May 9, 2017   (0 Comments - view/add)
AGTC and Collaborators Present New Data on the Natural History of X-Linked Retinoschisis (XLRS) at t »
AGTC and Collaborators Present New Data on the Natural History of X-Linked Retinoschisis (XLRS) at the Association for Res...
Wednesday, May 3, 2017   (0 Comments - view/add)
Mysterious Molecule’s Function in Skin Cancer Identified »
Mysterious Molecule’s Function in Skin Cancer Identified Non-coding RNA SPRIGHTLY plays important role in tumor growth...
Tuesday, May 2, 2017   (0 Comments - view/add)
Altor BioScience Corporation Announces FDA Fast Track Designation for Lead Candidate ALT-803 in Pati »
Altor BioScience Corporation Announces FDA Fast Track Designation for Lead Candidate ALT-803 in Patients with Non-Muscle I...
Tuesday, May 2, 2017   (0 Comments - view/add)
University of Miami Health System Starts Clinical Trial to Test Regenerative Treatment for Stroke »
University of Miami Health System Starts Clinical Trial to Test Regenerative Treatment for Stroke Pioneering study eval...
Monday, May 1, 2017   (0 Comments - view/add)
Cantex Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Development for CX-02 in Recur »
Cantex Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Development for CX-02 in Recurrent Glioblastoma...
Sunday, April 30, 2017   (0 Comments - view/add)
Friday, April 14, 2017   (0 Comments - view/add)
OBMedical Company Announces LABORVIEW® now available for Hospitals using Philips Fetal Monitoring Eq »
FOR IMMEDIATE RELEASE OBMedical Company Announces LABORVIEW® now available for Hospitals using Philips Fetal Monitor...
Tuesday, February 28, 2017   (0 Comments - view/add)
Mayo Clinic publishes genetic screen for Alzheimer's in African-Americans »
February 28, 2017   Mayo Clinic publishes genetic screen for Alzheimer's in African-Americans &nbs...
Monday, February 20, 2017   (0 Comments - view/add)
Stem Cell Company Combining Stem Cell Therapy with Hyperbaric Oxygen Treatment »
Stem Cell Company Combining Stem Cell Therapy with Hyperbaric Oxygen Treatment TAMPA, Fla. , Feb. 20, 2017 /PRNewswi...
Thursday, February 9, 2017   (0 Comments - view/add)
Prevacus to Begin Phase 1 Clinical Studies of PRV-002 for the Treatment of Concussion »
Prevacus to Begin Phase 1 Clinical Studies of PRV-002 for the Treatment of Concussion February 14, 2017 TALLAHASS...

Displaying page 1 of 3
1  |  2  |  3

Abbott

BioFlorida, Inc. | 6742 Forest Hill Blvd., Suite 256 | West Palm Beach, FL 33413
(P) 561-653-3839 admin@bioflorida.com
Membership Management Software Powered by YourMembership  ::  Legal